Myriad’s UroSuite offers germline, somatic and genomic genetic tests to help providers determine the best prostate cancer treatment options for their patients.
The article presents information on prostate cancer and the Prostate Cancer Risk Management Programme introduced by the Great Britain Department of Health (DoH), which stipulates that any man can have a prostate specific antigen (PSA) test if he ...
A prostate cancer diagnosis can be scary. Your imagination might be working overtime, playing out best- and worst-case scenarios. It’s normal. There’s so much to consider about which prostate cancer treatment is right for you, and the unknown can be unsettling. ...
Prostate-specific antigen testing for prostate cancer: the case for informed consent. Med J Aust. 1998; 169 (1):9–10. [ PubMed ]McCredie M, Cox B (1998) Prostate-specific antigen testing for prostate cancer: the case for informed consent. Med J Aust 169(1):9–10...
When testing for prostate cancer, as many as 75% of men with a raised prostate-specific antigen (PSA) have a benign biopsy result. Little is known about the psychological effect of this result for these men. In all, 330 men participating in the prostate
Understanding the chemistry underlying the interaction of pharmacological chaperones with their target proteins will facilitate the design of more efficient drugs with greater therapeutic potential.doi:10.5694/mja18.00324Brooks DougOlver Ian NEsterman Adrian JThe Medical journal of Australia...
Oliver Sartor, MD, board professor, cancer research, Tulane University, discusses the controversies surrounding PSA screening for prostate cancer. Sartor says PSA testing is becoming increasingly controversial. Different guidelines call for different strategies, creating a lack of consistency in the field....
BMC Family Practice BioMed Central Research article PSA testing for prostate cancer: an online survey of the views and reported practice of General Practitioners in the UK To describe general practitioners' current beliefs, knowledge and self-reported practices in prostate cancer screening, we conducted...
Some patients with prostate cancer have genetic mutations that may impact their treatment. A comprehensive, on-site genetic testing program, pioneered by urologists, could help to close the gap for this underutilized resource, reports a study in Urology
Men who are diagnosed with low-risk prostate cancer usually opt for active surveillance—a monitoring of their cancer over time without undergoing treatments that would cause side effects. In many men, the cancer never grows and poses no threat, but in others, the cancer begins to grow and tr...